Seven Eight Capital, LP United Therapeutics Corp Transaction History

Seven Eight Capital, LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	SELL	$228.26 - $319.04 $480,943 - $672,217	-2,107 Reduced 44.91%	2,585 $823,000
Q1 2024 May 13, 2024	BUY	$210.76 - $249.51 $988,885 - $1.17 Million	4,692 New	4,692 $1.08 Million
Q2 2022 Aug 04, 2022	SELL	$174.81 - $241.14 $349,270 - $481,797	-1,998 Closed	0 $0
Q1 2022 May 11, 2022	BUY	$166.16 - $213.96 $331,987 - $427,492	1,998 New	1,998 $358,000
Q2 2020 Aug 06, 2020	SELL	$92.74 - $125.82 $510,070 - $692,010	-5,500 Closed	0 $0
Q1 2020 May 14, 2020	SELL	$79.39 - $115.35 $2.01 Million - $2.92 Million	-25,287 Reduced 82.14%	5,500 $522,000
Q4 2019 Feb 13, 2020	BUY	$78.31 - $95.34 $415,043 - $505,302	5,300 Added 20.79%	30,787 $2.71 Million
Q3 2019 Nov 14, 2019	SELL	$74.85 - $85.99 $3.18 Million - $3.65 Million	-42,500 Reduced 62.51%	25,487 $2.03 Million
Q2 2019 Aug 12, 2019	BUY	$76.06 - $120.81 $4.36 Million - $6.92 Million	57,300 Added 536.17%	67,987 $5.31 Million
Q1 2019 May 15, 2019	BUY	$107.15 - $126.84 $1.15 Million - $1.36 Million	10,687 New	10,687 $1.25 Million

672

42.3M

194K

295K

Ticker UTHR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,516,300
Market Cap $16.2B
Description
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertensio...

Get notified when there are updates to the investment portfolio of Seven Eight Capital, LP, based on Form 13F filings with the SEC.

Stay updated on Seven Eight Capital, LP with notifications on news.